31
Session · 31 of 35
Pharmacoeconomics
Pharmacoeconomic analysis informs reimbursement decisions with growing US uptake post-IRA. The session covers ICER value frameworks and controversies, EU EUnetHTA JCA implementation, NICE methods and evidence requirements, pharmacoeconomic modelling (Markov, partitioned survival, MAIC), HTA bodies globally (NICE, CADTH, IQWiG, HAS), and IRA Medicare negotiation impact on prices. Discussion addresses outcomes research methodologies, cost-effectiveness vs cost-utility analysis, patient-reported outcomes in value assessment, equity in pharmacoeconomic frameworks, and value-based contracting for gene therapies.
Topics covered in this session
- ICER value frameworks
- EU JCA implementation
- NICE methods
- Markov pharmacoeconomic modelling
- HTA bodies globally
- IRA price impact
- Patient-reported outcomes value
- Value-based gene therapy contracts
Other Sessions
Explore the full WCPD 2027 program
- 01Drug Discovery & Design
- 02Clinical Pharmacology
- 03Pharmacogenomics & Precision Medicine
- 04Drug Delivery Systems
- 05Toxicology & Safety Pharmacology
- 06Regulatory Science & Policy
- 07Pharmacovigilance
- 08Biopharmaceuticals
- 09Pharmaceutical Manufacturing
- 10mRNA & RNA Therapeutics
- 11Antibody Engineering
- 12Oligonucleotide Therapeutics
- 13AI for Drug Design
- 14Real-World Evidence
- 15Adaptive Clinical Trials
- 16Pharmaceutical Quality
- 17Generic & Biosimilars
- 18Access & Pricing
- 19Antimicrobial Drug Development
- 20Antiviral Drug Development
- 21Anticancer Therapies
- 22CNS Drugs
- 23Endocrine Drugs
- 24Pediatric Drug Development
- 25Geriatric Pharmacology
- 26Herbal & Natural Products
- 27Drug Repurposing
- 28Orphan Drugs
- 29Combination Therapies
- 30Drug-Drug Interactions
- 32Compounding Pharmacy
- 33Hospital Pharmacy
- 34Targeted Protein Degraders
- 35Pharmacovigilance Innovation